Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GNA15 | P30679 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948897 | 0.88 | MMP13 (0.56) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL13948896 | 0.88 | ALDH1A1 (0.70) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL13948890 | 0.86 | ALDH1A1 (0.55) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL23229951 | 0.86 | PRMT6 (0.59) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL13969804 | 0.86 | KDM4E (0.48) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL24061764 | 0.86 | CHRM2 (0.60) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL17227470 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL9420019 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL8809177 | 0.83 | ALDH1A1 (0.79) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL1108585 | 0.82 | KDM4E (0.61) | KDM4EALDH1A1HTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9208538-A | — | — | None | — | — | JP | disclosed |
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021011834-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6136863-A | ETHERIFIED AROMATIC AMINE | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2000-10-24 | — | — | US | disclosed |
| JP-H09208538-A | ANTIFUNGAL AGENT | POLA CHEM IND INC | 1997-08-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KDM4E 786/4885ALDH1A1 3223/4885HTT 4140/4885 |
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | KDM4E 1795/4885ALDH1A1 1020/4885HTT 1420/4885 |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | KDM4E 4302/4885ALDH1A1 1945/4885HTT 1864/4885 |
| US-10011609-B2 | Heterocyclic compounds | GPR55, GPR68, GPR65 | KDM4E 4216/4885ALDH1A1 1896/4885HTT 1215/4885 |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | ORAI1, ATP2A3, ANO1 | KDM4E 3292/4885ALDH1A1 1498/4885HTT 2742/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | KDM4E 847/4885ALDH1A1 239/4885HTT 2477/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | KDM4E 4286/4885ALDH1A1 1939/4885HTT 1669/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | KDM4E 847/4885ALDH1A1 239/4885HTT 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.